All companies › SYRE

SYRE · Spyre Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells14
Research cases0
Last filing2026-09-02

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-01 — King-Jones Heidy · sold 4,845 @ $86.40 2026-09-01 — King-Jones Heidy · sold 16,548 @ $87.20 2026-09-01 — King-Jones Heidy · sold 6,206 @ $88.17 2026-09-01 — King-Jones Heidy · sold 400 @ $89.38 2026-09-01 — Burrows Scott L · sold 900 @ $86.25 2026-09-01 — Burrows Scott L · sold 4,384 @ $87.11 2026-09-01 — Burrows Scott L · sold 2,016 @ $88.03 2026-09-01 — Burrows Scott L · sold 200 @ $89.04 2026-09-01 — Turtle Cameron · sold 2,500 @ $86.36 2026-09-01 — Turtle Cameron · sold 8,400 @ $87.15 2026-09-01 — Turtle Cameron · sold 3,700 @ $88.06 2026-09-01 — Turtle Cameron · sold 400 @ $89.07 2026-09-02 — King-Jones Heidy · sold 400 @ $90.00 2026-09-02 — Burrows Scott L · sold 18,232 @ $89.35
2026-09-012026-09-02

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

King-Jones Heidy See Remarks
Burrows Scott L Chief Financial Officer
Turtle Cameron Chief Executive Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $SYRE is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-02', 'insider_name': 'King-Jones Heidy', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 400.0, 'price': 90.0, 'value': 36000.0, 'is_buy': False}, {'transaction_date': '2026-09-02', 'insider_name': 'Burrows Scott L', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 18232.0, 'price': 89.35, 'value': 1629029.2, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'King-Jones Heidy', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 4845.0, 'price': 86.4, 'value': 418608.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'King-Jones Heidy', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 16548.0, 'price': 87.2, 'value': 1442985.6, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'King-Jones Heidy', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 6206.0, 'price': 88.17, 'value': 547183.02, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'King-Jones Heidy', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 400.0, 'price': 89.38, 'value': 35752.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Burrows Scott L', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 900.0, 'price': 86.25, 'value': 77625.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Burrows Scott L', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 4384.0, 'price': 87.11, 'value': 381890.24, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Burrows Scott L', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 2016.0, 'price': 88.03, 'value': 177468.48, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Burrows Scott L', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 200.0, 'price': 89.04, 'value': 17808.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Turtle Cameron', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market sell', 'shares': 2500.0, 'price': 86.36, 'value': 215900.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Turtle Cameron', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market sell', 'shares': 8400.0, 'price': 87.15, 'value': 732060.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Turtle Cameron', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market sell', 'shares': 3700.0, 'price': 88.06, 'value': 325822.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Turtle Cameron', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market sell', 'shares': 400.0, 'price': 89.07, 'value': 35628.0, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for SYRE today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.